Literature DB >> 28419405

Optical Coherence Tomography Angiography Features in Melanocytoma of the Optic Nerve.

Adriano Carnevali, Lea Querques, Ilaria Zucchiatti, Vincenzo Scorcia, Francesco Bandello, Giuseppe Querques.   

Abstract

Optic disc melanocytoma (ODM) is a pigmented tumor with malignant potential characterized clinically as a dark brown to black lesion with feathery margins. The authors report a case of ODM and describe the utility of optical coherence tomography angiography (OCTA) in detecting superficial tumor vascularization. This case report demonstrated the ability of OCTA to reveal the fine abnormal retinal vasculature on the surface of the lesion, a characteristic of ODM, which has been previously correlated with tumor growth. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:364-366.]. Copyright 2017, SLACK Incorporated.

Entities:  

Mesh:

Year:  2017        PMID: 28419405     DOI: 10.3928/23258160-20170329-14

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  4 in total

1.  Involvement of circulatory disturbance in optic disk melanocytoma with visual dysfunction.

Authors:  Iku Kikuchi; Satoru Kase; Yuki Hashimoto; Kiriko Hirooka; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-02-04       Impact factor: 3.117

2.  Optic nerve head melanocytoma: Optical coherence tomography/angiography features.

Authors:  Vishal Raval; Rajeev Reddy; Swathi Kaliki; Taraprasad Das; Arun D Singh
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

3.  Optical coherence tomography angiography characteristics of optic disc melanocytoma.

Authors:  Nan Zhou; Xiaolin Xu; Wenbin Wei
Journal:  BMC Ophthalmol       Date:  2020-10-27       Impact factor: 2.209

4.  Optic disc melanocytoma with normal tension glaucoma and angle closure glaucoma: Two case reports.

Authors:  Dae Sung Kim; Hae Min Park; Han Woong Lim; Won June Lee
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.